Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2013-07-17 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces a final agreement with the former Chairman, Dr. Daniel Vasella, detailing transitional services and consulting agreements. There are no financial statements, detailed financial performance data, or comprehensive management analysis present. The document is a regulatory announcement about management arrangements rather than a full report or financial disclosure. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or any detailed financial or governance report. It also does not fit into categories like Board/Management Information (MANG) since it does not announce a change in board members but rather an agreement with a former chairman. Given the nature of the document as a regulatory announcement filed on Form 6-K with no substantive financial data, the best classification is Regulatory Filings (RNS). The document length (7064 characters) and content support this classification with high confidence.
2013-07-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing top-line results from a Phase III clinical trial for a drug (secukinumab) showing superiority to a competitor drug. It includes detailed clinical trial results, study design, and forward-looking statements about regulatory submissions and future presentations. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not an earnings release, call transcript, or management report. It is a regulatory filing providing material information about clinical trial results and company developments but does not fit into more specific categories like M&A, capital updates, or governance. Given the nature of Form 6-K filings and the content, the best classification is Regulatory Filings (RNS).
2013-07-08 English
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a letter from Novartis AG to the SEC referencing the Form 20-F for the fiscal year ended December 31, 2012, which was filed earlier. The letter responds to an SEC inquiry and is signed by the CFO and General Counsel. The document length is short (1016 characters) and it does not contain any financial statements or substantive financial data itself. It is a correspondence related to a regulatory filing rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS) as it is a response letter to the SEC rather than the actual Form 20-F or an audit report.
2013-07-02 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing that the FDA has granted Breakthrough Therapy designation to Novartis' investigational drug serelaxin (RLX030) for acute heart failure. The document contains no financial statements or detailed financial data, but rather a regulatory announcement about a clinical development milestone and related information. It is not an annual or interim report, earnings release, or any other financial report. It is a regulatory filing providing material information to the SEC and investors. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (over 12,000 characters), so it is not a mere report publication announcement. There is no indication of officer certification or voting results, so other categories do not apply.
2013-06-21 English
Regulatory Filings 2013
Regulatory Filings
2013-06-19 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing clinical trial results (BOLERO-3 Phase III trial) for the drug Afinitor in advanced breast cancer. It includes detailed information about the trial design, drug indications, safety information, and forward-looking statements. There are no financial statements or comprehensive financial performance data presented. The document is primarily a regulatory announcement of clinical trial results and related information, not a financial report or earnings release. Form 6-K filings typically serve as regulatory filings for foreign issuers to disclose material information to the SEC and investors. Given the nature and content, this filing best fits the category of Regulatory Filings (RNS).
2013-05-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.